BPC-157 Dosage: The Numbers and Where They Come From
The commonly referenced doses
| Route | Common amount | Frequency | Typical target |
|---|---|---|---|
| Subcutaneous | 250–500 mcg | 1–2× daily | Systemic, tendon, muscle |
| Oral (capsule or liquid) | 250–500 mcg | 1–2× daily | Gut-directed |
Protocols usually run four to eight weeks. Some split the daily amount into two doses on the reasoning that the peptide clears quickly; no study has compared once-daily against twice-daily on any outcome, so that split is a hypothesis rather than a finding.
Where these numbers came from
Rodent studies used microgram-per-kilogram quantities across a wide range, and reported effects at doses spanning several orders of magnitude — which is itself informative: the animal literature does not identify a narrow effective window. The 250–500 mcg figure is roughly what you get from scaling a mid-range rodent dose to a human body weight, and that scaling is exactly the step regulators do not accept.
Species differ in metabolic rate, clearance and receptor distribution. Allometric conversion is a starting point for designing a Phase 1 trial, not a substitute for running one. For BPC-157 no Phase 1 dose-finding study has been published, so the gap between the animal data and the syringe has never been bridged by evidence. Seethe main BPC-157 guide for what the animal studies actually found.
Reconstitution and syringe units
This is where most mistakes happen, and it is pure arithmetic. The amount of bacteriostatic water you add changes the concentration — never the amount of peptide in the vial. More water means a larger, easier-to-measure draw for the same dose.
| Vial | Water | Concentration | 250 mcg | 500 mcg | Doses per vial (250 mcg) |
|---|---|---|---|---|---|
| 5 mg | 1 ml | 5,000 mcg/ml | 5 units | 10 units | 20 |
| 5 mg | 2 ml | 2,500 mcg/ml | 10 units | 20 units | 20 |
| 5 mg | 2.5 ml | 2,000 mcg/ml | 12.5 units | 25 units | 20 |
| 5 mg | 3 ml | 1,667 mcg/ml | 15 units | 30 units | 20 |
| 10 mg | 2 ml | 5,000 mcg/ml | 5 units | 10 units | 40 |
| 10 mg | 2.5 ml | 4,000 mcg/ml | 6.25 units | 12.5 units | 40 |
| 10 mg | 5 ml | 2,000 mcg/ml | 12.5 units | 25 units | 40 |
Notice the last column: doses per vial never changes with water volume. A 5 mg vial contains twenty 250 mcg doses whether you dissolve it in 1 ml or 3 ml. If a protocol appears to stretch a vial further by adding more water, the arithmetic is wrong somewhere.
A practical note on small draws. At 5 units, a misread of half a unit is a 10% dosing error. Reconstituting with more water pushes the same dose into a larger, more readable volume — at the cost of a more dilute vial that takes longer to finish, which brings the roughly four-week post-reconstitution stability window into play. Our reconstitution guide covers the technique.
Formula: concentration = peptide (mcg) ÷ water (ml). Volume = dose ÷ concentration. One unit on a U-100 insulin syringe = 0.01 ml. Values are for laboratory reference only.
Oral versus injectable
BPC-157 is unusual among peptides in surviving gastric acid, and that property is not marketing — it is why oral administration appears in the rat studies on intestinal healing. The practical split in the literature:
- Gut-directed research — oral, where the target tissue is the thing the compound passes through.
- Tendon, muscle, systemic — subcutaneous, which is the route used in most of the animal work on those targets.
What is not established: whether oral dosing achieves meaningful systemic exposure in humans. Surviving the stomach is not the same as being absorbed into circulation at a useful concentration, and no human pharmacokinetic study has measured it.
Injection-site placement
A common belief is that BPC-157 should be injected near the injury. The animal literature does not settle this — studies report effects from systemic administration as well as local, and no study has compared the two head to head for the same injury. Anyone choosing based on "near the site works better" is following a plausible hypothesis, not a result.
What is genuinely unknown
- The effective dose in a human. No dose-finding study exists.
- The maximum safe dose. Animal toxicology reported no observable toxicity across a wide range and no LD50 in the studies that looked — but that is animal data, and absence of an observed ceiling is not a human safety margin.
- Optimal duration and whether cycling matters. No data.
- Whether the compound in the vial is what the label says — the variable that dominates all of the above. Our supplier guide covers documentation.
BPC-157 — 5 mg / 10 mg — American Peptides
At microgram dosing, the difference between a 5 mg and a 10 mg vial changes your syringe math, not your dose. Batch purity documentation matters more here than vial size — HPLC and mass-spec COA provided per batch.
We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.
Frequently asked questions
What is the standard BPC-157 dosage?
There is no standard, because no human dose-finding trial has ever been run. Protocols in circulation cluster around 250–500 mcg once or twice daily for four to eight weeks. Those numbers come from practice, loosely scaled from animal studies — they are not a trial result and should not be described as one.
How many units of BPC-157 is 250 mcg?
It depends entirely on how much bacteriostatic water you added. A 5 mg vial reconstituted with 2 ml gives 2,500 mcg/ml, so 250 mcg is 0.1 ml — 10 units on a U-100 insulin syringe. Add 2.5 ml instead and the same dose becomes 12.5 units. The water volume changes the units, never the amount of peptide.
What dose did the animal studies actually use?
Rodent studies typically used microgram-per-kilogram quantities, and a wide range of them. Converting animal doses to humans is not a matter of multiplying by body weight — species differ in metabolic rate and clearance, which is why regulators require dedicated human dose-finding studies. Nobody has run one for BPC-157.
Should BPC-157 be taken orally or by injection?
It depends on the target. BPC-157 is unusually stable in gastric acid, which is why oral administration appears in the rat studies on intestinal healing and is used for gut-directed research. For tendon, muscle or systemic targets, subcutaneous injection is the route used in most animal work.
How long should a BPC-157 protocol run?
Community protocols typically run four to eight weeks. There is no evidence establishing an optimal duration, no data on what happens with longer use, and no washout research. The four-to-eight-week convention is convention, not a finding.
Sources
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011;17(16):1612–32. PubMed
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. Journal of Applied Physiology, 2011;110(3):774–80. PubMed
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021;27(4):8–13 — an uncontrolled case series, and the only primary human report. PubMed
- Registered but not yet reported: Phase 2 BPC-157 trial in hamstring strain, NCT07437547. Registration is not evidence.
- Bacteriostatic Water for Injection, USP — prescribing information. DailyMed
Related guides
- BPC-157: side effects, evidence and regulatory status
- BPC-157 + TB-500 blend: the dose-halving trap
- TB-500 dosage
- How to reconstitute peptides
- Peptide reconstitution calculator